Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2008Clinical Cancer Research

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTorsten TroweGilead Sciences (United States)SBSotiria BoukouvalaDemocritus University of ThraceKCKeith CalkinsNovartis (Switzerland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Trowe et al. (2008) studied this question.

synapsesocial.com/papers/6a7a4fbda51ded8e7b32a995https://doi.org/10.1158/1078-0432.ccr-07-4367
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor2002 · 1,587 citations
  2. 2The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.1991 · 127 citations
  3. 3Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors2006 · 830 citations
  4. 4PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors2007 · 128 citations
  5. 5Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain2005 · 3,557 citations